Seventeen patients with inoperable locoregional disease (epidermoid carcinoma of the esophagus) were treated only with two courses of intermediate-dose methotrexate (200 mg/m2 on day 1) and cisplatin (20 mg/m2/d for 5 days). According to the response criteria, 14 (82.4%) achieved a good response (GR) and 3 (17.6%) showed no response (NR). The median recurrence-free survival time was 5 months (range, 2 to 16 months) in seven patients with regular follow-up. Three patients are still alive and disease-free at 37+, 44+, and 51+ months. No patient received radiotherapy or surgery after chemotherapy until recurrence. This combination schedule appears to be effective in advanced esophageal carcinoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/1097-0142(19890715)64:2<371::aid-cncr2820640205>3.0.co;2-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Do Double-Expressor High-Grade B-Cell Lymphomas Really Need Intensified Treatment? A Report from the Real-Life Series of High-Grade B-Cell Lymphomas Treated with Different Therapeutic Protocols at the Institute of Oncology Ljubljana.
Biomedicines
January 2024
Division of Medical Oncology, Institute of Oncology, Zaloška Cesta 2, 1000 Ljubljana, Slovenia.
High-grade B-cell lymphomas with and and/or rearrangements are known for their aggressive clinical course and so are the ones with MYC and BCL2 protein overexpression. The optimal therapy for these lymphomas remains to be elucidated. A retrospective analysis of all diffuse large B-cell lymphomas and high-grade B-cell lymphomas with and and/or rearrangements diagnosed between 2017 and 2021 at the Institute of Oncology Ljubljana, Slovenia, has been performed.
View Article and Find Full Text PDFDose-Related Effect of Chemotherapy on Bone Mineral Density Among Pediatric Acute Lymphoblastic Leukemia Survivors.
J Pediatr Pharmacol Ther
February 2024
Division of Pediatric Hematology-Oncology (DJK), Department of Pediatrics, Rady Children's Hospital - San Diego, San Diego, CA.
Objectives: Reduced bone mineral density (BMD) can negatively affect lifelong skeletal health by -increasing the risk for developing osteopenia and osteoporosis. This study evaluated the relationship between BMD and cumulative doses of intravenous (IV) methotrexate (MTX) and glucocorticoids in pediatric acute lymphoblastic leukemia (ALL) survivors. The association between BMD and vitamin D concentrations measured at the time of entry into the long-term follow-up program was also assessed.
View Article and Find Full Text PDFFolinic Acid Over: Rescue of Intermediate Dose Methotrexate.
Clin Lymphoma Myeloma Leuk
April 2024
Sackler Faculty of Medicine Tel Aviv University, Ramat Aviv, Schneider Children's Medical Center of Israel, Petah Tikva, Israel. Electronic address:
A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma.
Cancers (Basel)
February 2023
Resonance, Inc., 5239 Jeffrey Keith Drive, Arlington, TN 38002, USA.
Primary central nervous system lymphoma (PCNSL) is a highly aggressive non-Hodgkin lymphoma that is confined within the CNS. Due to its ability to cross the blood-brain barrier, high-dose methotrexate (HDMTX) is the backbone for induction chemotherapy. This systematic review was conducted to observe outcomes among different HDMTX doses (low, <3 g/m; intermediate, 3-4.
View Article and Find Full Text PDFHigh efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up.
Sci Rep
June 2022
Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology, 5 WK Roentgen Str, 02-781, Warsaw, Poland.
Article Synopsis
- Primary mediastinal B-cell lymphoma (PMBL) has a high cure rate of 85-95%, with various treatment regimens including RCHOP and DAEPOCH-R; this study examined a protocol involving aggressive immunochemotherapy and intermediate-dose methotrexate.
- The study involved 124 patients, with a median follow-up of 9 years, showing impressive 5-year overall survival (94%) and progression-free survival (92%), influenced by PET-CT results post-chemotherapy.
- The intensive treatment showed low rates of severe side effects (0.8% treatment-related mortality) and late toxicities (2.4% for second malignancies and cardiotoxicity), indicating its effectiveness and safety in young
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!